Rani Therapeutics Holdings Inc(RANI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:29 PM ET (Korea 10/31 08:29)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.27 | Insider Own | 23.76% | Shs Outstand | 112.5M | Perf Week | -2.62% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | -8.57% | Insider Trans | 0.19% | Shs Float | 88.0M | Perf Month | -25.83% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.05 | Inst Own | 28.75% | Short Float | 9.27% | Perf Quarter | -26.37% |
| Income | -0.03B | P/S | 16.85 | EPS this Y | 61.11% | Inst Trans | 3.15% | Short Ratio | 13.92 | Perf Half Y | -37.23% |
| Sales | 0.00B | P/B | 1.69 | EPS next 5Y | 28.43% | ROA | -77.54% | Short Interest | 8.16M | Perf YTD | -56.3% |
| Book/sh | 0.35 | P/C | 1.53 | EPS past 3/5Y | 29.57% 11.92% | ROE | -179.1% | 52W High | -77.57% ($2.63) | Perf Year | -59.31% |
| Cash/sh | 0.38 | P/FCF | - | Sales past 3/5Y | - 28.73% | ROIC | -72.71% | 52W Low | 2.84% ($0.57) | Perf 3Y | -69.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 70.84% | Gross Margin | 84.21% | Volatility(W/M) | 4.67% 6.61% | Perf 5Y | -97.43% |
| Dividend TTM | - | EV/Sales | 8.39 | Sales Y/Y TTM | 306.42% | Oper. Margin | -675.78% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.31 | EPS Q/Q | 78.43% | Profit Margin | -618.04% | RSI (14) | 31.42 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.31 | Sales Q/Q | - | SMA20 | -13.37% ($0.68) | Beta | 0.59 | Target Price | $7.2 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/13 | SMA50 | -23.22% ($0.77) | Rel Volume | 1.15 | Prev Close | $0.61 |
| Employees | 71 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 20% 84.49% | SMA200 | -36.76% ($0.93) | Avg Volume(3M) | 0.59M | Price | $0.59 |
| IPO | 2021/7/30 | Option/Short | Yes/Yes | Trades | 863 | Volume | 676,291 | Change | -2.54% |
💊 Rani Therapeutics is a clinical-stage biotech company headquartered in California, USA. It develops an oral delivery platform that delivers biologic drugs (such as antibodies and peptides), which were previously administered only by injection, in the form of swallowable capsules. Through its proprietary capsule technology, the company is researching a method that automatically injects the drug after it passes through the gastrointestinal tract, with a focus on overcoming the convenience limitations of injectable therapies.
Over the past 1 year, on the lower side
78% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
RANI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +61.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,685. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IBBQ Invesco Nasdaq Biotechnology ETF <0.01% 
IWC iShares Micro-Cap ETF <0.01% 
BIB ProShares Ultra Nasdaq Biotechnology 2X Shares <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
URA Global X Uranium ETF 5.0B 
NLR VanEck Uranium Nuclear Energy ETF 3.2B 
URNM Sprott Uranium Miners ETF 1.8B 
URNJ Sprott Junior Uranium Miners ETF 314M 
URAA Direxion Daily Uranium Industry Bull 2X ETF 25M It ranks #374 of 595 in the industry
Based on market cap of $82M.
RLYB#372 Rallybio Corp $85M PER 3.5 
TNYA#373 Tenaya Therapeutics Inc $84M PER - RANI#374 Rani Therapeutics Holdings Inc $82M PER - 
CRBP#375 Corbus Pharmaceuticals Holdings Inc $82M PER - 
ATRA#376 Atara Biotherapeutics Inc $80M PER - 
FAQ
What kind of company is RANI?
RANI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RANI?
The market cap of RANI is approximately $82M, ranking 4,569 within its sector.
What is the 52-week high and low for RANI?
RANI has recorded a 52-week high of $2.63 and a low of $0.57.
